Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb study of Hib-MenCY-TT co-administered with Rotarix, Prevnar 13, and Havrix in infants
2013-003459-39Phase 3
- Sponsor
- GSK
- Start
- Jul 2015
- Modality
- Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Haemophilus influenzae type b and meningococcal vaccine, human rotavirus RIX4414 strain vaccine, Prevnar 13, Hepatitis A virus vaccine and haemophilus influenzae type b vaccine in Haemophilus influenzae type b disease (Hib), meningococcal group C disease, meningococcal disease and 3 more (2 arms), sponsored by GSK. Primary endpoint: Immunogenicity with respect to the components of the co-administered vaccines.
02
Drugs
Haemophilus influenzae type b and meningococcal vaccinehuman rotavirus RIX4414 strain vaccinePrevnar 13Hepatitis A virus vaccinehaemophilus influenzae type b vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal group C diseasemeningococcal diseaserotaviral diarrheapneumococcal disease
Beyond the preview
Go deeper on 2013-003459-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003459-39.